Molecular biology of lung cancer.
Sydney, Australia. In J Thorac Dis, 31 Oct 2013
Lung cancer mutations have been identified in v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), BRAF and the parallel phosphatidylinositol 3-kinase (PI3K) pathway oncogenes and more recently in MEK and HER2 while structural rearrangements in ALK, ROS1 and possibly rearranged during transfection (RET) provide new therapeutic targets.
Villejuif, France. In Lancet, 18 Oct 2013
New predisposition genes have been reported and key somatic events, such as BRAF mutation, directly translated into therapeutic management.
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Nantes, France. In N Engl J Med, 12 Oct 2013
METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status.
[Companion diagnostics and reimbursement system].
Tokyo, Japan. In Rinsho Byori, May 2013
In July 2011, the FDA published draft guidance for the development of CoDx, which recommends the co-development of CoDx and new drugs as the best practice, and then the FDA approved vemurafenib and the BRAF-V600-E gene mutation assay simultaneously as a typical example of the co-development of a new drug and its CoDx.